Route of Administration Determines Induction of T-Cell-Independent Humoral Responses to Adeno-Associated Virus Vectors

Molecular Therapy

Volumn 1, Issue 4, 2000, Pages 323-329

  Xiao, Weidong ^a,b   Chirmule, Narendra ^a,b   Schnell, Michael A ^a,b   Tazelaar, John ^a,b   Hughes, Joseph V ^a,b   Wilson, James M ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b WISTAR INSTITUTE   (United States)

Author keywords

AAV2; Gene therapy; Liver; Neutralizing antibodies; T cell independent

Indexed keywords

VIRUS ANTIBODY;

ADENO ASSOCIATED VIRUS; ANIMAL; ARTICLE; B LYMPHOCYTE; BAGG ALBINO MOUSE; BIOSYNTHESIS; C57BL MOUSE; GENE THERAPY; GENE VECTOR; GENETICS; HUMAN; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; INJECTION; INTRAVENOUS DRUG ADMINISTRATION; LIVER; LYMPHOCYTE ACTIVATION; MACACA; MOUSE; MOUSE MUTANT; NUDE MOUSE; PORTAL VEIN; SPLEEN; T LYMPHOCYTE;

ANIMALS; ANTIBODIES, VIRAL; B-LYMPHOCYTES; DEPENDOVIRUS; GENE THERAPY; GENETIC VECTORS; HUMANS; IMMUNOLOGIC MEMORY; INJECTIONS; INJECTIONS, INTRAVENOUS; LIVER; LYMPHOCYTE ACTIVATION; MACACA MULATTA; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, NUDE; PORTAL VEIN; SPLEEN; T-LYMPHOCYTES;

EID: 0034169676     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1006/mthe.2000.0045     Document Type: Article

References (24)

1. Herzog R. W., Yang E. Y., Couto L. B., Hagstrom J. N., Elwell D., Fielfs P. A., Burton M., Bellinger D. A., Read M. S., Brinkhous K. M., Podsakoff G. M., Nichols T. C., Kurtzman G. J., High K. A. Long term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector. Nat. Med. 5:1999;56-63.
2. Muzyczka N. Use of adeno-associated virus as a general transduction vector in mammalian cells. Curr. Top. Microbiol. Immunol. 158:1992;97-129.
3. Snyder R. O., Niao C., Meuse L., Tubb J., Donahue B. A., Lin H-F., Stafford D. W., Patel S., Thompson A. R., Nichols T., Read M. S., Bellinger D. A., Brinkhous K. M., Kay M. A. Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors. Nat. Med. 5:1999;64-70.
4. Verma I. M., Somia N. Gene therapy - Promises, problems and prospects. Nature. 389:1997;239-242.
5. Xiao X., Li J., Samulski R. J. Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector. J. Virol. 70:1996;8098-8108.
6. Berns K., Bohenzky R. A. Adeno-associated viruses: An update. Adv. Virus Res. 32:1987;243-306.
7. Chirmule N., Propert K., Magosin S., Qian G., Qian R., Wilson J. M. Immune responses to DNA vectors in humans. Gene Ther. 6:1999;1574-1583.
8. Jooss K., Yang Y., Fisher K. J., Wilson J. M. Transduction of dendritic cells by DNA viral vectors directs the immune responses to transgene products in muscle fibers. J. Virol. 72:1998;4212-4223.
9. Samulski R. J., Zhu X., Xiao X., Brook J. D., Housman D. E., Epstein N., Hunter L. A. Targeted integration of adeno-associated virus (AAV) into human chromosome 19. EMBO J. 10:1991;3941-3950.
10. Vincent-Lacaze N., Snyder R. O., Gluzman R., Bohl D., Lagarde C., Danos O. Structure of adeno-associated virus vector DNA following transduction of the skeletal muscle. J. Virol. 73:1999;1949-1955.
11. Manning W. C., Zhou S., Bland M. P., Escobedo J. A., Dwarki V. Transient immunosuppression allows transgene expression following readministration of adeno-associated viral vectors. Hum. Gene Ther. 9:1998;477-485.
12. Xiao W. D., Chirmule N., Berta S., McCullough B., Gao G.-P., Wilson J. M. Gene therapy vectors based on adeno-associated virus type I. J. Virol. 73:1999;3994-4003.
13. Koeberl D. D., Alexander I. E., Halbert C. L., Russell D. W., Miller A. D. Persistent expression of human clotting factor IX from mouse liver after intravenous injection of adeno-associated virus vectors. Proc. Natl. Acad. Sci. USA. 94:1997;1426-1431.
14. Nakai H., Herzog R. W., Hagstrom J. N., Walter J., Kung S. H., Yang E. Y., Tai S. J., Iwaki Y., Kurtzman G. J., Fisher K. J., Colosi P., Couto L. B., High K. A. Adeno-associated virus vector mediated gene transfer of human blood coagulation factor IX into mouse liver. Blood. 91:1998;4600-4607.
15. Xiao W., Berta S. C., Lu M. M., Moscioni D., Tazelaar J., Wilson J. M. Adeno-associated virus as a vector for liver-directed gene therapy. J. Virol. 72:1998;10222-10226.
16. Yang Y., Trinchieri G., Wilson J. M. Recombinant IL-12 prevents formation of blocking IgA antibodies to recombinant adenovirus and allows repeated gene therapy to mouse lung. Nat. Med. 1:1995;890-893.
17. Yang Y., Greenough K., Wilson J. M. Transient immune blockade prevents formation of neutralizing antibody to recombinant adenovirus and allows repeated gene transfer to mouse liver. Gene Ther. 3:1996;412-420.
18. Rajewsky K. Clonal selection and learning in the antibody system. Nature. 381:1996;751-758.
19. Szomolanyi-Tsuda E., Welsh R. T-cell-independent antiviral antibody responses. Immunology. 10:1998;431-435.
20. Bachmann M., Zinkernagel R. The influence of virus structure on antibody responses and virus serotype formation. Immunol. Today. 17:1996;553-558.
21. Saarinen U., Chorba T., Tattersall P., Young N., Anderson L., Palmer E., Coccia P. Human parvovirus B19-induced epidemic acute red cell aplasia in patients with hereditary hemolytic anemia. Blood. 67:1986;1411-1417.
22. Moskalenko M., Chen L., VanRoey M., Donahue B. A., Snyder R. O., McArthur J. G., Patel S. D. Epitope mapping of human anti-ade-associated virus type 2 neutralizing antibodies: Implications for gene therapy and virus structure. J. Virol. 74:2000;1761-1766.
23. Chirmule N., Xiao W., Truneh A., Zoltick P., Wilson J. Humoral immunity to AAV2 vectors following administration to murine and non-human primate muscle. J. Virol. 74:2000;2420-2425.
24. Halbert C. L., Standaert T. A., Wilson C. B., Miller D. A. Successful readministration of adeno-associated virus vectors to the mouse lung requires transient immunosuppression during the initial exposure. J. Virol. 72:1998;9795-9805.